title: Bilateral transient hearing loss associated with vincristine therapy: case report.
abstract: Vincristine, adriamycin, and dexamethasone (VAD) chemotherapy protocol is first-choice treatment in newly diagnosed multiple myeloma patients in many centers. Sudden hearing loss associated with vincristine therapy is a rarely observed event in the VAD protocol. We describe a 69-year old male patient diagnosed with multiple myeloma 7 months ago who developed sudden bilateral hearing loss related to vincristine therapy. This uncommon adverse effect of vincristine is discussed and the literature reviewed.
authors.affiliation: Inonu University, School of Medicine, Department of Haematology, Turgut Ozal Medical Center, Malatya, Turkey. masevinc@usa.net
authors.forename: I
authors.initials: I
authors.lastname: Aydogdu
authors.forename: O
authors.initials: O
authors.lastname: Ozturan
authors.forename: I
authors.initials: I
authors.lastname: Kuku
authors.forename: E
authors.initials: E
authors.lastname: Kaya
authors.forename: A
authors.initials: A
authors.lastname: Sevinc
authors.forename: R
authors.initials: R
authors.lastname: Yildiz
mesh_terms: D000368:Aged; D000972:Antineoplastic Agents, Phytogenic / Q000009:adverse effects*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D003907:Dexamethasone / Q000009:adverse effects / Q000627:therapeutic use; D004317:Doxorubicin / Q000009:adverse effects / Q000627:therapeutic use; D006312:Hearing Loss, Bilateral / Q000139:chemically induced*; D006801:Humans; D008297:Male; D009101:Multiple Myeloma / Q000188:drug therapy; D014750:Vincristine / Q000009:adverse effects* / Q000627:therapeutic use
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D014750:Vincristine; D003907:Dexamethasone; D004317:Doxorubicin